EW
Edwards Lifesciences Corporation
November 2, 2026 · market open
- Rarity
- 1.22
- Peak move
- +4.05%
- Float cap
- $52.6B
Edwards Lifesciences Corporation develops and sells medical technologies for structural heart disease. Its portfolio includes transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical heart valves and repair products. These therapies are used by cardiac surgeons and interventional cardiologists to treat patients with aortic, mitral, tricuspid, and pulmonic valve disease and other advanced cardiovascular conditions.
Where do you see this going?
no votes yetVote to see the split.
What we found
no events · 0 from SEC or newswire · 0 timed with the moveNothing found.We searched SEC filings, the newswires and the open web across the three days around this move and found no public information that explains it.